Insulet price target lowered to $180 from $219 at Baird

Baird lowered the firm’s price target on Insulet to $180 from $219 and keeps a Neutral rating on the shares. The firm said 3Q was another quarter of strong U.S. Omnipod growth for PODD and management continues making good progress on G7 and L2 integration efforts, early O5 EU launch efforts, and the Secure T2 O5 trial, all of which Baird sees as supportive of solid continued growth over the next couple/few years.